ISB 1342 not checked

Ichnos Sciences SA

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
0 active
1 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“ISB-1342 is CD38 x CD3 BEAT® 1.0 bispecific antibody. ISB 1342 is administered by intravenous (IV) infusion or subcutaneous injection (SC)”In the company’s words, NCT03309111 on ClinicalTrials.gov
Tested for
Relapsed/Refractory Multiple Myeloma
Main trialPhase 1
“The purpose of this study is to assess safety, efficacy, pharmacokinetic (PK)/pharmacodynamic (PD), and immunogenicity with ISB 1342 in subjects with relapsed/refractory multiple myeloma.”In the company’s words, NCT03309111 on ClinicalTrials.gov

Other drugs for Relapsed/Refractory Multiple Myeloma

All 133 drugs for Relapsed/Refractory Multiple Myeloma

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1Completed 15 Dec 2023 Study of ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow ISB 1342

Following is part of Solo: you see every change to ISB 1342 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in